Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1994-7-8
|
| pubmed:abstractText |
Thirty-four patients with chronic myelogenous leukemia in chronic phase were treated with busulfan 16 mg/kg and cyclophosphamide 120 or 200 mg/kg before allogeneic bone marrow transplantation from an HLA-identical sibling. Cyclosporine, methotrexate and prednisone were used for graft-versus-host disease (GVHD) prophylaxis. The actuarial probabilities of survival and relapse-free survival at 82 months were 71%. With a maximum follow-up of 2471 days, none of the patient experienced hematologic or clinical relapse. In one patient reappearance of host cells was documented 180 days post-transplant which disappeared 277 days post-transplant and the patient is in complete hematological and cytogenetic remission 5 years after the transplant. The probability of transplant-related mortality was 29% while the probability of moderate to severe acute graft-versus-host disease was 38%. This study indicates that busulfan and cyclophosphamide are a good conditioning regimen for marrow transplantation in patients with chronic myeloid leukemia in chronic phase.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Busulfan,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
197-201
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8205089-Adolescent,
pubmed-meshheading:8205089-Adult,
pubmed-meshheading:8205089-Bone Marrow Transplantation,
pubmed-meshheading:8205089-Busulfan,
pubmed-meshheading:8205089-Child,
pubmed-meshheading:8205089-Combined Modality Therapy,
pubmed-meshheading:8205089-Cyclophosphamide,
pubmed-meshheading:8205089-Cyclosporine,
pubmed-meshheading:8205089-Dose-Response Relationship, Drug,
pubmed-meshheading:8205089-Female,
pubmed-meshheading:8205089-Graft vs Host Disease,
pubmed-meshheading:8205089-Humans,
pubmed-meshheading:8205089-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:8205089-Male,
pubmed-meshheading:8205089-Methotrexate,
pubmed-meshheading:8205089-Middle Aged,
pubmed-meshheading:8205089-Prednisolone,
pubmed-meshheading:8205089-Transplantation, Homologous
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
|
| pubmed:affiliation |
Divisione di Ematologia, Ospedale di Pesaro, Italy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|